FOR IMMEDIATE RELEASE: August 31, 2006
Schumer Visits Bristol-Myers Squibb With CEO Peter Dolan – BMS To Reaffirm Commitment To Operations In Central New York
Schumer Tours Bristol-Myers Squibb’s Syracuse Facility
Bristol-Myers Squibb in Syracuse Is One Of The Few Major Biological Manufacturers In The World Approved By The Federal Drug Administration
U.S. Senator Charles E. Schumer today visited the Bristol-Myers Squibb facility in Syracuse and met with CEO Peter R. Dolan. Schumer toured the Bristol-Myers Squibb’s biologics development and manufacturing operations, where Mr. Dolan reaffirmed the company’s commitment to Central New York. Bristol-Myers is one of the few major biological manufacturing plants in the world approved by the Federal Drug Administration (FDA).
“Syracuse has been the ideal home for Bristol-Myers’ manufacturing facility,” Schumer said. “The fact that the FDA has just approved a drug that was developed right here in Central New York is proof of the great innovation, skilled work force, and foresight of the people working here. Some scientists go their whole lives without having one drug passed. It is great news that Bristol-Myers is committed to staying in this community, and I look forward to continue working with them to grow more in this region.”
The Bristol-Myers facility in Syracuse has transitioned from manufacturing mature products to manufacturing growth products based on infermentation technology. While penicillin manufacturing was the bread and butter for Bristol for many decades, they are now investing in innovative, high-tech biologics development and manufacturing at the Syracuse facility. In 2001, Bristol-Myers Squibb had 85 employees dedicated to biologics development and manufacturing, now there are over 400 employees dedicated to that area. The total number of employees has remained at about 800 during this transition. A new drug, Orencia, received FDA approval in December of 2005, and was developed at Bristol-Myers Squibb in Syracuse. Bristol-Myers Squibb is currently developing new biologic drugs which will be discussed during this tour.
Joining Schumer and Mr. Dolan will be Irwin Davis, President and CEO of the Metropolitan Development Association, James Robinson, Chairman of the Board of Directors at Bristol-Myers Squibb, Mariclaire Payawal, VP, Office of the CEO, Dick Thompson, Senior VP of Policy and Government Affairs, Robert Zito, Senior VP Corporate and Business Communications, Chief Communications Officer, Jeff MacDonald, Associate Director of Corporate and Business Communications, Linda Jordan, Associate Director Corporate and Business Communications, William McGarry, VP and Senior Counsel for Technical Operations, Joseph Tarnowski, Senior VP Biologics Manufacturing and Process Development, Steven Lee, VP and General Manager Biologics Manufacturing and Process Development, Thomas Vanden Boom, Director of Biotechnology Development and Jeffrey Robbins, Associate Director of Biotechnology Manufacturing.